{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=2", "query": { "intervention": "cohort 3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 5391, "total_pages": 540, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T23:26:27.834Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01380743", "title": "Drug-drug Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pompe Disease" ], "interventions": [ { "name": "duvoglustat", "type": "DRUG" }, { "name": "rhGAA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amicus Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2011-10-31", "completion_date": "2013-01-04", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01380743" }, { "nct_id": "NCT03651271", "title": "Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Metastatic Cancer", "Advanced Prostate Cancer" ], "interventions": [ { "name": "Nivolumab Monotherapy", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Ipilimumab and Combination for Metastatic Cancer", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-10-17", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 6, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03651271" }, { "nct_id": "NCT03168035", "title": "Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Lymphoma" ], "interventions": [ { "name": "NC-4016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NanoCarrier Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2013-11", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03168035" }, { "nct_id": "NCT06054217", "title": "Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Meibomian Gland Dysfunction", "Demodex Infestation of Eyelid", "Blepharitis", "Demodectic Blepharitis" ], "interventions": [ { "name": "Vehicle of TP-03", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarsus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-08-01", "completion_date": "2024-06-15", "has_results": false, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 2, "location_summary": "Northridge, California • Shelby, North Carolina", "locations": [ { "city": "Northridge", "state": "California" }, { "city": "Shelby", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06054217" }, { "nct_id": "NCT02656199", "title": "Change In Diaphragmatic Thickness Predicts Extubation Success", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mechanical Ventilation Complication" ], "interventions": [ { "name": "Diaphragm Ultrasound", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Albert Einstein Healthcare Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2015-01", "completion_date": "2017-01-13", "has_results": true, "last_update_posted_date": "2020-03-09", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02656199" }, { "nct_id": "NCT03221426", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1007, "start_date": "2017-10-09", "completion_date": "2025-04-23", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 14, "location_summary": "Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03221426" }, { "nct_id": "NCT07498335", "title": "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Berger Disease", "Bergers Disease", "IgA Nephropathy", "Immunoglobulin A Nephropathy", "Primary IgAN", "Nephritis IgA Type, Nephropathy IgA Type" ], "interventions": [ { "name": "Drug: Atrasentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 28, "start_date": "2026-08-06", "completion_date": "2032-12-13", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 4, "location_summary": "Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Neptune City", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07498335" }, { "nct_id": "NCT00766116", "title": "Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "5-Azacitidine", "type": "DRUG" }, { "name": "Gemtuzumab ozogamicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 50, "start_date": "2005-07", "completion_date": "2014-09-26", "has_results": true, "last_update_posted_date": "2019-02-18", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 3, "location_summary": "La Jolla, California • Stanford, California • Atlanta, Georgia", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00766116" }, { "nct_id": "NCT01060384", "title": "Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "ofatumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 46, "start_date": "2010-03-29", "completion_date": "2018-01-01", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 2, "location_summary": "Grand Island, Nebraska • Omaha, Nebraska", "locations": [ { "city": "Grand Island", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01060384" }, { "nct_id": "NCT06153355", "title": "A First-In-Human Study of LY3839840 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY3839840", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 140, "start_date": "2023-12-04", "completion_date": "2025-05-22", "has_results": false, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-09-30T23:26:27.834Z", "location_count": 2, "location_summary": "Anaheim, California • Madison, Wisconsin", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06153355" } ] }